The effect of altitude change on anemia treatment response in hemodialysis patients

American Journal of Epidemiology

Volumn 173, Issue 7, 2011, Pages 768-777

  Brookhart, M Alan ^a,b   Bradbury, Brian D ^c,d   Avorn, Jerry ^a   Schneeweiss, Sebastian ^a   Winkelmayer, Wolfgang C ^a,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b IL   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

altitude; anemia; erythropoietin; kidney failure, chronic; risk factors

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON;

ALTITUDE; ANEMIA; BASELINE SURVEY; BLOOD; CONFIDENCE INTERVAL; DATABASE; DISEASE TREATMENT; HEALTH IMPACT; HEALTH SURVEY; HYPOTHESIS TESTING; HYPOXIA;

ADULT; AGED; ALTITUDE; ARTICLE; CONTROLLED STUDY; FEEDBACK SYSTEM; FEMALE; HEALTH SURVEY; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPOXIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICARE; REFRACTORY ANEMIA; TREATMENT RESPONSE; UNITED STATES;

AGED; ALTITUDE; ANEMIA; CONFOUNDING FACTORS (EPIDEMIOLOGY); ERYTHROPOIETIN; FEMALE; HEMATOCRIT; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, STATISTICAL; RENAL DIALYSIS; RESIDENCE CHARACTERISTICS; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

UNITED STATES;

EID: 79953903045     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq423     Document Type: Article

References (36)

1. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73-78. (Pubitemid 17052741)
2. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584-590. (Pubitemid 28385655)
3. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098. (Pubitemid 44749317)
4. Ebben JP, Gilbertson DT, Foley RN, et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1(6): 1205-1210.
5. Kausz AT, Solid C, Pereira BJ, et al. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease? Am J Kidney Dis. 2005;45(1):136-147. (Pubitemid 40038054)
6. Gilbertson DT, Ebben JP, Foley RN, et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol. 2008;3(1):133-138.
7. Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(4):1077-1083.
8. Ishani A, Solid CA, Weinhandl ED, et al. Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrol Dial Transplant. 2008;23(5):1682-1689. (Pubitemid 351767748)
9. Bradbury BD, Danese MD, Gleeson M, et al. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodial-ysis patients with hemoglobin levels persistently below 11 g/dL. Clin J Am Soc Nephrol. 2009;4(3):630-637.
10. Rosenberger C, Rosen S, Shina A, et al. Hypoxia-inducible factors and tubular cell survival in isolated perfused kidneys. Kidney Int. 2006;70(1):60-70. (Pubitemid 44000121)
11. Maxwell P. HIF-1: an oxygen response system with special relevance to the kidney. J Am Soc Nephrol. 2003;14(11): 2712-2722. (Pubitemid 37305633)
12. Gunaratnam L, Bonventre JV. HIF in kidney disease and development. J Am Soc Nephrol. 2009;20(9):1877-1887.
13. Huang LE, Ho V, Arany Z, et al. Erythropoietin gene regulation depends on heme-dependent oxygen sensing and assembly of interacting transcription factors. Kidney Int. 1997;51(2): 548-552. (Pubitemid 27088173)
14. Rolfs A, Kvietikova I, Gassmann M, et al. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible fac-tor-1. J Biol Chem. 1997;272(32):20055-20062. (Pubitemid 27340110)
15. Lok CN, Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem. 1999;274(34): 24147-24152.
16. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7): 1037-1044.
17. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematology/the education program of the American Society of Hematology. Hematology. 2006;29- 35:507.
18. Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104(8):2263-2268. (Pubitemid 39331821)
19. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023.
20. Blumberg A, Keller H, Marti HR. Effect of altitude on eryth-ropoiesis and oxygen affinity in anaemic patients on maintenance dialysis. Eur J Clin Invest. 1973;3(2):93-97.
21. Bosman DR, Osborne CA, Marsden JT, et al. Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabet Med. 2002;19(1):65-69. (Pubitemid 34146639)
22. Quick J, Eichenberger A, Binswanger U. Stimulation of erythropoietin in renal insufficiency by hypobaric hypoxia. Nephrol Dial Transplant. 1992;7(10):1002-1006.
23. Robach P, Fulla Y, Westerterp KR, et al. Comparative response of EPO and soluble transferrin receptor at high altitude. Med Sci Sports Exerc. 2004;36(9):1493-1498; discussion 1492. (Pubitemid 39202616)
24. Brookhart MA, Schneeweiss S, Avorn J, et al. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol. 2008;19(7):1389-1395.
25. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4):1049-1060. (Pubitemid 19026037)
26. SAS Institute, Inc. Version 9.1 computer software. Cary, NC: SAS Institute, Inc; 2003.
27. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12(11):2465-2473. (Pubitemid 33021125)
28. Bradbury BD, Wang O, Critchlow CW, et al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis. 2008;51(1):62-70. (Pubitemid 350296516)
29. Roberts TL, Obrador GT, St Peter WL, et al. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int. 2004;66(6):2429-2436.
30. Gunnell J, Yeun JY, Depner TA, et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999;33(1):63-72. (Pubitemid 29031210)
31. Bradbury BD, Critchlow CW, Weir MR, et al. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant. 2009;24(3):919-925.
32. Weil JV, Jamieson G, Brown DW, et al. The red cell mass- arterial oxygen relationship in normal man. Application to patients with chronic obstructive airway disease. J Clin Invest. 1968;47(7):1627-1639.
33. Sawka MN, Convertino VA, Eichner ER, et al. Blood volume: importance and adaptations to exercise training, environmental stresses, and trauma/sickness. Med Sci Sports Exerc. 2000;32(2):332-348. (Pubitemid 30108111)
34. Luks AM, Johnson RJ, Swenson ER. Chronic kidney disease at high altitude. J Am Soc Nephrol. 2008;19(12):2262-2271.
35. Winkelmayer WC, Liu J, Brookhart MA. Altitude and all-cause mortality in incident dialysis patients. JAMA. 2009; 301(5):508-512.
36. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11): 1516-1523.